Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
13 March 2025Portfolio NewsMontara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board
12 March 2025Portfolio NewsQurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
5 March 2025Portfolio NewsTRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
25 February 2025Portfolio NewsHarness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference
18 February 2025Portfolio NewsLoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
10 February 2025Portfolio NewsAdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer- 4 February 2025Portfolio NewsAustralian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
- 3 February 2025Portfolio NewsAdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
27 January 2025Portfolio NewsHarness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline- 15 January 2025SV NewsSV Therapeutics 2024 Year in Review
9 January 2025Portfolio NewsAlchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
26 December 2024SV NewsKate Bingham on innovation in drug development on World at One Radio 4
